Monday July 6, 2020 0 comments
WESTMINSTER -- Flagship Biosciences, providers of expert tissue data insights, announced that the launch of a new clinical diagnostics immuno-oncology service, TissueInsight.
TissueInsight provides CLIA-reportable PD-L1 results along with data about the tumor microenvironment (TME), the company said.
“Flagship’s TissueInsight is a service that aids pathologists, oncologists, and immunologists in optimizing care for cancer patients,” said Trevor Johnson, Flagship CEO.
“It provides immediate image analysis results without the need for an upfront monetary investment, internal development time or validation. TissueInsight reports can also be customized using additional biomarkers and image analysis.”
Flagship said its exclusive, targeted testing in its College of American Pathologists (CAP)-accredited and Clinical Laboratory Improvement Amendments (CLIA)-certified lab delivers the highly accurate tissue scoring needed for precision medicine.
Combined with its award-winning technology and sign-off from its experienced pathologists for every client, TissueInsight gives rapid, data-rich tissue interpretations and removes the inherent variability of subjective manual tissue scoring.
Along with its CLIA-reportable results, TissueInsight TME data includes information on tumor infiltrating lymphocytes (TILs) and macrophages.
“I’m extremely pleased to bring this new clinical diagnostics service to the market,” said Johnson.
“Flagship’s scientific process, machine learning, and laboratory capabilities are enabling us to work with clinicians to expand immuno-oncology diagnostic tissue tests that will make their work more efficient and better help them to deliver on the promise of precision medicine for their patients.”